Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M76,918Revenue $M6,932Net Margin (%)25.6Z-Score16.3
Enterprise Value $M75,938EPS $7.8Operating Margin %36.0F-Score8
P/E(ttm))35.9Cash Flow Per Share $7.4Pre-tax Margin (%)35.9Higher ROA y-yY
Price/Book8.010-y EBITDA Growth Rate %25.7Quick Ratio1.7Cash flow > EarningsY
Price/Sales9.25-y EBITDA Growth Rate %20.1Current Ratio2.1Lower Leverage y-yY
Price/Cash Flow20.5y-y EBITDA Growth Rate %43.7ROA % (ttm)16.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)22.4Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M237ROI % (ttm)19.7Gross Margin Increase y-yN

Gurus Latest Trades with BIIB

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIIBRon Baron 2014-06-30 Add$274 - $320.13
($300.74)
$ 325.068%Add 41.76%8,632
BIIBJoel Greenblatt 2014-06-30 Sold Out -0.02%$274 - $320.13
($300.74)
$ 325.068%Sold Out0
BIIBGeorge Soros 2014-06-30 Sold Out -0.02%$274 - $320.13
($300.74)
$ 325.068%Sold Out0
BIIBJohn Burbank 2014-06-30 Sold Out -0.01%$274 - $320.13
($300.74)
$ 325.068%Sold Out0
BIIBGeorge Soros 2014-03-31 Buy 0.02%$273.518 - $351.94
($316.4)
$ 325.063%New holding, 7500 sh.7,500
BIIBJoel Greenblatt 2014-03-31 Buy 0.02%$273.518 - $351.94
($316.4)
$ 325.063%New holding, 3931 sh.3,931
BIIBRon Baron 2014-03-31 Buy 0.01%$273.518 - $351.94
($316.4)
$ 325.063%New holding, 6089 sh.6,089
BIIBJohn Burbank 2014-03-31 Buy 0.01%$273.518 - $351.94
($316.4)
$ 325.063%New holding, 783 sh.783
BIIBVanguard Health Care Fund 2014-03-31 Reduce-0.24%$273.518 - $351.94
($315.54)
$ 325.063%Reduce -32.19%599,400
BIIBRay Dalio 2014-03-31 Sold Out -0.04%$273.518 - $351.94
($316.4)
$ 325.063%Sold Out0
BIIBRay Dalio 2013-12-31 Add0.03%$223.85 - $295.88
($258.53)
$ 325.0626%Add 208.67%19,057
BIIBJohn Hussman 2013-12-31 Sold Out -0.99%$223.85 - $295.88
($258.53)
$ 325.0626%Sold Out0
BIIBVanguard Health Care Fund 2013-12-31 Reduce-0.47%$223.85 - $295.88
($258.53)
$ 325.0626%Reduce -39.09%884,000
BIIBJohn Hussman 2013-09-30 Add0.33%$206.53 - $248.13
($223.63)
$ 325.0645%Add 50%75,000
BIIBMario Gabelli 2013-09-30 Add$206.53 - $248.13
($223.63)
$ 325.0645%Add 81.87%3,310
BIIBRay Dalio 2013-09-30 Reduce-0.01%$206.53 - $248.13
($223.63)
$ 325.0645%Reduce -41.27%6,174
BIIBFrank Sands 2013-06-30 Add0.71%$192.77 - $240.86
($213.68)
$ 325.0652%Add 27.6%4,565,921
BIIBMario Gabelli 2013-06-30 Reduce$192.77 - $240.86
($213.68)
$ 325.0652%Reduce -25.1%1,820
BIIBJohn Hussman 2013-06-30 Reduce-1.45%$192.77 - $240.86
($213.68)
$ 325.0652%Reduce -80.62%50,000
BIIBPRIMECAP Management 2013-06-30 Reduce-0.28%$192.77 - $240.86
($213.68)
$ 325.0652%Reduce -5%18,246,809
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIIB is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BIIB Ron Baron 2014-06-308,63200.01+41.76%
BIIB Mario Gabelli 2014-06-304,17500.01+16.46%
BIIB Frank Sands 2014-06-304,891,4632.063.9+0.38%
BIIB PRIMECAP Management 2014-06-3017,258,3117.286-1.39%
BIIB Vanguard Health Care Fund 2014-06-30559,7000.240.47-6.62%
BIIB George Soros 2014-06-30000Sold Out
BIIB Joel Greenblatt 2014-06-30000Sold Out
BIIB John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BIIB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SCANGOS GEORGE ACEO 2014-09-02Sell1,128$345.47-6.24view
SCANGOS GEORGE ACEO 2014-08-01Sell1,128$332.93-2.71view
SCANGOS GEORGE ACEO 2014-07-16Sell12,316$312.373.69view
Posner Brian SDirector 2014-06-20Sell605$3152.83view
Posner Brian SDirector 2014-06-13Sell700$310.54.32view
SCANGOS GEORGE ACEO 2014-06-02Sell484$318.931.56view
Holtzman Steven HEVP Corporate Development 2014-05-19Sell1,221$289.1512.02view
SCANGOS GEORGE ACEO 2014-05-01Sell2,123$285.5613.43view
Holtzman Steven HEVP Corporate Development 2014-04-17Sell1,221$29111.31view
SCANGOS GEORGE ACEO 2014-04-01Sell2,123$308.425.02view

Press Releases about BIIB :

    Quarterly/Annual Reports about BIIB:

    News about BIIB:

    Articles On GuruFocus.com
    Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
    Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
    Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
    Weekly 52-Week Highs Highlight: ORLY, LLL, BIIB, NVS Feb 09 2014 
    Weekly CFO Sells Highlight: CSOD, UTX, MEMS, SBAC, BIIB Sep 22 2013 
    PRIMECAP Trims Top Biotechs and More Aug 30 2013 
    Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
    52-Week High Guru Stocks: BIIB, GE, BDX, IR, PFE Sep 24 2012 
    Weekly Top Insider Sells: GOOG, FIS, ORCL, and BIIB Aug 06 2012 
    Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 

    More From Our Partners
    Stock Market News for September 16, 2014 - Market News Sep 16 2014 - ZACKS

    More From Other Websites
    Zacks Rank #1 Additions for Tuesday Sep 16 2014
    Biogen/AbbVie Report Positive Data on MS Drug Zinbryta Sep 15 2014
    Nasdaq Falls Hard, But Apple Resilient On iPhone Orders Sep 15 2014
    3 Stocks Underperforming Today In The Drugs Industry Sep 15 2014
    Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers Sep 13 2014
    Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada Sep 12 2014
    Biogen Reports Positive Two-Year Data on MS Drug Plegridy Sep 12 2014
    Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the... Sep 12 2014
    Stocks Show Modest Losses; Biotechs Pressured Again Sep 11 2014
    Short Sellers Remain Vigilant Against Biotechs Sep 11 2014
    Biogen Idec, Inc. Suddenly Struggling To Keep Up With The Biotech Joneses Sep 11 2014
    New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl... Sep 11 2014
    PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in... Sep 11 2014
    Stocks Turn Higher After Soft Start; U.S. Silica Jumps Sep 10 2014
    Receptos MS Drug Yields More Good Data; Stock Jumps Sep 10 2014
    Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval Sep 10 2014
    New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet... Sep 10 2014
    3 Stocks Pushing The Drugs Industry Lower Sep 09 2014
    J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig Sep 08 2014
    [video] 3 Biotech picks: Gilead, Biogen & Celgene Sep 05 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK